SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis
16 references·0 citing·46 second hop
Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis (2020)Application of Managed Entry Agreements f…Pricing of pharmaceuticals is becoming a major challenge for health systems (2020)Pricing of pharmaceuticals is…Managed Entry Agreements: Policy Analysis From the European Perspective (2020)Managed Entry Agreements: Pol…Unmet Medical Need: An Introduction to Definitions and Stakeholder Perceptions (2019)Unmet Medical Need: An Introd…Addressing the Value of Gene Therapy and Enhancing Patient Access to Transformative Treatments (2018)Addressing the Value of Gene …Payers’ experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia (2017)Payers’ experiences with conf…Advanced therapy medicinal products: current and future perspectives (2016)Advanced therapy medicinal pr…Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group (2012)Challenges in the Development…Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers (2010)Risk sharing arrangements for…Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers (2010)Linking payment to health out…Coverage with Evidence Development: Applications and issues (2010)Coverage with Evidence Develo…Canʼt Get No Satisfaction? Will Pay for Performance Help? (2010)Canʼt Get No Satisfaction? Wi…The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration (2009)The PRISMA Statement for Repo…The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration (2009)The PRISMA statement for repo…Value based pricing for NHS drugs: an opportunity not to be missed? (2008)Value based pricing for NHS d…OFT, VBP: QED? (2007)OFT, VBP: QED?Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents (2003)Differential Pricing for Phar…Using Value of Information Analysis to Prioritise Health Research (2006)Exploring Uncertainty in Cost-Effectiveness Analysis (2008)Subgroups and Heterogeneity in Cost-Effectiveness Analysis (2008)Examining the Use of Real‐World Evidence in the Regulatory Process (2019)Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions (2009)Health systems in transition. (2010)Managed entry agreements for pharmaceuticals: the European experience (2013)Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study (2015)How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries (2017)Cost-Effectiveness in Health and Medicine (1996)Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices—Modeling Studies (2003)Methods for the Economic Evaluation of Health Care Programmes (2005)The Future of Precision Medicine: Potential Impacts for Health Technology Assessment (2018)Cost-effectiveness of precision medicine: a scoping review (2019)Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group (2020)Assessing the economic challenges posed by orphan drugs (2007)The High Cost of Cancer Drugs and What We Can Do About It (2012)Economic burden of cancer across the European Union: a population-based cost analysis (2013)Challenges in Advanced Therapy Medicinal Product Development: A Survey among Companies in Europe (2018)Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy (2019)The Landscape of Cellular and Gene Therapy Products: Authorization, Discontinuations, and Cost (2019)Measuring inconsistency in meta-analyses (2003)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (2009)Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement (2009)PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews (2021)The PRISMA 2020 statement: an updated guideline for reporting systematic reviews (2021)The PRISMA 2020 statement: an updated guideline for reporting systematic reviews (2021)Intergenerational Equity: An Exploration of the ‘Fair Innings’ Argument (1997)Effectiveness and efficiency of search methods in systematic reviews of complex evidence: audit of primary sources (2005)What Is Real-World Data? A Review of Definitions Based on Literature and Stakeholder Interviews (2017)Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland (2022)Prevalence of unmet health care need in older adults in 83 countries: measuring progressing towards universal health coverage in the context of global population ageing (2023)Structured content and data management—enhancing acceleration in drug development through efficiency in data exchange (2023)The cost of drug development: A systematic review (2011)The $2.6 Billion Pill — Methodologic and Policy Considerations (2015)Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research (2016)Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis (2020)Evidence-based public policy making for medicines across countries: findings and implications for the future (2021)Lowering drug prices and enhancing pharmaceutical affordability: an analysis of the national volume-based procurement (NVBP) effect in China (2021)A Contribution to the Theory of Taxation (1927)A Theory of Incentives in Procurement and Regulation (1993)The price of innovation: new estimates of drug development costs (2003)Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report—Part II (2009)Investments in Pharmaceuticals Before and After TRIPS (2011)Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden (2014)ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe (2016)
this work references cited by second hop

References

  • 2009The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration28,382 cited
  • 2009The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration10,686 cited
  • 2003Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents317 cited
  • 2010Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers287 cited
  • 2010Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers255 cited
  • 2008Value based pricing for NHS drugs: an opportunity not to be missed?230 cited
  • 2016Advanced therapy medicinal products: current and future perspectives171 cited
  • 2012Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group161 cited
  • 2020Pricing of pharmaceuticals is becoming a major challenge for health systems145 cited
  • 2019Unmet Medical Need: An Introduction to Definitions and Stakeholder Perceptions125 cited
  • 2010Canʼt Get No Satisfaction? Will Pay for Performance Help?124 cited
  • 2017Payers’ experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

117 cited
  • 2018Addressing the Value of Gene Therapy and Enhancing Patient Access to Transformative Treatments115 cited
  • 2007OFT, VBP: QED?114 cited
  • 2020Managed Entry Agreements: Policy Analysis From the European Perspective113 cited
  • 2010Coverage with Evidence Development: Applications and issues93 cited
  • Cited by

    No citing works inside the corpus for this window.